Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Syndax Pharmaceuticals Inc
SNDXCurrent price
13.73 USD
-0.03 USD (-0.22%)
Last closed
13.71 USD
Company
www.syndax.com
ISIN
US87164F1057
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 177 082 624 USD
Yield for 12 month
-38.81 %
1Y
3Y
5Y
10Y
15Y
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. Address: 35 Gatehouse Drive, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
36.85 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+126 576 000 USD
Current Quarter
+12 500 000 USD
Last Quarter
+3 500 000 USD
Current Year
-12 000 USD
Last Year
-454 000 USD
Current Quarter
+12 498 000 USD
Last Quarter
-40 837 000 USD
Key Figures SNDX
1 year
3 years
5 years
10 years
EBITDA
-321 200 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-48.67 %
PEG Ratio
–
Return On Equity TTM
-81.88 %
Wall Street Target Price
36.85 USD
Revenue TTM
16 000 000 USD
Book Value
4.28 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
33 297.40 %
Dividend Yield
–
Gross Profit TTM
139 709 000 USD
Earnings per share
-3.64 USD
Diluted Eps TTM
-3.64 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SNDX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SNDX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation SNDX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
48.22
Price Sales TTM
73.57
Enterprise Value EBITDA
-105.26
Price Book MRQ
3.21
Financials SNDX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SNDX
For 52 weeks
13.26 USD
25.34 USD
50 Day MA
17.86 USD
Shares Short Prior Month
10 603 810
200 Day MA
20.27 USD
Short Ratio
6.54
Shares Short
14 396 481
Short Percent
17.00 %
BeatStart